Upgrade to SI Premium - Free Trial

Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"

March 12, 2026 9:26 AM
Jefferies analyst Akash Tewari reiterated a Buy rating and $103.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments